2,000 patients treated with OssDsign® Catalyst in the U.S.
Uppsala, September 13, 2023. OssDsign AB (publ.) today announces that the company’s orthobiologic business continues to accelerate its successful commercialization in the U.S. To this day, 2,000 patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst, up from 1,000 patients treated in May.With 2,000 patients treated, OssDsign Catalyst continues to show exponential growth from earlier records of 1,000 treated patients in May and 500 patients treated in January. “It is great to see how our orthobiologics business continues its successful